ALGS — Aligos Therapeutics Share News
0.000.00%
Last trade - 00:00- $29.85m
- -$0.47m
- $2.19m
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue
Aligos Therapeutics, Inc. expected to post a loss of $1.07 a share - Earnings Preview
Aligos Therapeutics Inc expected to post a loss of $1.07 a share - Earnings Preview
Aligos rises on receiving upfront payment from hepatitis B drug license deal
U.S. STOCKS ON THE MOVE-Netflix, J.B. Hunt, Arxis
U.S. STOCKS ON THE MOVE-Abbott, J.B. Hunt, Myseum
U.S. STOCKS ON THE MOVE-Abbott, PepsiCo, Blue Owl
U.S. STOCKS ON THE MOVE-Hamilton Lane, Meta, Marsh
Aligos jumps after $445 mln China licensing deal for hepatitis B drug
Brief: Aligos Therapeutics Announces First Interim Analysis Results From The Phase 2 B-Supreme Study Of Pevifoscorvir Sodium In Participants With Chronic Hepatitis B Virus Infection And Grant Of FDA Fast Track Designation
Aligos Therapeutics Q4 net loss narrows
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Aligos rises as mid‑stage trial for hepatitis B drug advances
Brief: Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Brief: Aligos Therapeutics Strengthens Senior Leadership Team With The Appointment Of James Hassard As Executive Vice President, Chief Commercial Officer